Mint Explainer | How promising are new cancer treatments?
Separately, on 17 November, Sellas Life Sciences announced positive results from its phase 3 trial of galinpepimut-S (GPS), an experimental therapeutic vaccine for acute myeloid leukemia (AML), an aggressive blood cancer. The peptide vaccine showed a nine-month improvement in overall survival, delivering a median overall survival of 24 months versus less than 15 months for best available therapy. GPS also showed a 41% reduction in the risk of death.